Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.
https://european-biotechnology.com/wp-content/uploads/2024/04/ADAPTIMMUNE-_JamesNoble.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-11-11 12:24:442016-11-11 12:24:44Adaptimmune downgrades trial design after FDA clinical hold
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Adaptimmune downgrades trial design after FDA clinical hold
Latest NewsOxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.